ReviewBiological psychiatry2014
Neuroimaging biomarkers for early drug development in schizophrenia.
Review in Biological psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Neuronal effects of nicotine during auditory selective attention in schizophrenia.Human brain mapping · 2016Trial
- Hippocampal volume in affective and non-affective psychosis.Schizophrenia research · 2025Article
- Smaller anterior hippocampal subfields in the early stage of psychosis.Translational psychiatry · 2024Article
- Functional Connectivity Biomarkers in Schizophrenia.Advances in neurobiology · 2024Review
- Non-invasive temporal interference electrical stimulation of the human hippocampus.Nature neuroscience · 2023Article
- Animal Model Reveals Mechanism of Hippocampal Hyperactivity in Psychosis.Schizophrenia bulletin · 2023Article
- Increased amplitude of hippocampal low frequency fluctuations in early psychosis: A two-year follow-up study.Schizophrenia research · 2022Article
- Subtyping Schizophrenia Patients Based on Patterns of Structural Brain Alterations.Schizophrenia bulletin · 2022Article
- Neuroimaging Biomarkers in Schizophrenia.The American journal of psychiatry · 2021Review
- Intrinsic Connectivity Patterns of Task-Defined Brain Networks Allow Individual Prediction of Cognitive Symptom Dimension of Schizophrenia and Are Linked to Molecular Architecture.Biological psychiatry · 2021Article
- Individual-specific functional connectome biomarkers predict schizophrenia positive symptoms during adolescent brain maturation.Human brain mapping · 2020Article
- Selective Review of Neuroimaging Findings in Youth at Clinical High Risk for Psychosis: On the Path to Biomarkers for Conversion.Frontiers in psychiatry · 2020Review
- Hyperactivity and Reduced Activation of Anterior Hippocampus in Early Psychosis.The American journal of psychiatry · 2019Article
- Optogenetic induction of the schizophrenia-related endophenotype of ventral hippocampal hyperactivity causes rodent correlates of positive and cognitive symptoms.Scientific reports · 2018Article
- Correlation Between Levels of Delusional Beliefs and Perfusion of the Hippocampus and an Associated Network in a Non-Help-Seeking Population.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2018Article
- Prefrontal Cortex Dysfunction Increases Susceptibility to Schizophrenia-Like Changes Induced by Adolescent Stress Exposure.Schizophrenia bulletin · 2017Article
- Connectomic correlates of response to treatment in first-episode psychosis.Brain : a journal of neurology · 2017Article
- Converging effects of diverse treatment modalities on frontal cortex in schizophrenia: A review of longitudinal functional magnetic resonance imaging studies.Journal of psychiatric research · 2017Review
- Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.Neuropharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Given the relative inability of currently available antipsychotic treatments to adequately provide sustained recovery and improve quality of life for patients with schizophrenia, new treatment strategies are urgently needed. One way to improve the therapeutic development process may be an increased use of biomarkers in early clinical trials. Reliable biomarkers that reflect aspects of disease pathophysiology can be used to determine if potential treatment strategies are engaging their desired biological targets. This review evaluates three potential neuroimaging biomarkers: hippocampal hyperactivity, gamma-band deficits, and default network abnormalities. These deficits have been widely replicated in the illness, correlate with measures of positive symptoms, are consistent with models of disease pathology, and have shown initial promise as biomarkers of biological response in early studies of potential treatment strategies. Two key features of these deficits, and a guiding rationale for the focus of this review, are that the deficits are not dependent upon patients' performance of specific cognitive tasks and they have analogues in animal models of schizophrenia, greatly increasing their appeal for use as biomarkers. Using neuroimaging biomarkers such as those proposed here to establish early in the therapeutic development process if treatment strategies are having their intended biological effect in humans may facilitate development of new treatments for schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.